This is how the Install App dialog will look like once your App goes live.
SightGlass Vision: 3-Year Clinical DataSightGlass Vision has released 36-month data from the pivotal CYPRESS myopia control study, which it says demonstrates the safety and efficacy of SightGlass Vision spectacle lenses with Diffusion Optics Technology for myopic children.
Lenses that incorporate SightGlass Vision Diffusion Optics Technology use thousands of micro-dots that softly scatter light to reduce contrast on the retina.
The company said the SightGlass technology significantly reduced both axial length and cycloplegic SER progression versus the control.
The three-year data also showed low device-related adverse event rates. No serious adverse events were reported. Visual performance for distance and near was excellent (20/20 or better) and remained stable, and low contrast visual acuity was similar to control.
While the lens proved beneficial at all ages, the slowing of myopia progression among children ages six to seven years at the initiation of treatment was of particular note.
SightGlass Vision CEO Andrew Sedgwick said the CYPRESS clinical trial purposefully included a subset of younger children to examine this gap in myopia control research and treatment options.
The results of the study, Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years (Laughton, D. et al.) were to be presented at the 2022 American Academy of Optometry annual meeting in San Diego in late October.